|
MaxCyte is capturing value and commercially validating its unique technology through partnerships with biotech and pharmaceutical partners. Below are representative partners that have been publicly disclosed
Partners MaxCyte and Geron initiated a research and development plan to further develop the GMP compliant MaxCyte system for use in a closed-system manufacturing process being developed by Geron for their GRNVAC1 immunotherapeutic product. Upon completion of optimization and evaluation studies, the agreement provides an option for a commercial license to MaxCyte's technology and a supply contract, as well as rights to reference MaxCyte's FDA Master File in Geron's regulatory submissions.
 MaxCyte, Inc. and Medinet Co., Ltd. (TSE: 2370) signed an exclusive license, development and supply agreement to use MaxCyte's proprietary cell loading system to support clinical studies and commercialization of Medinet's cancer immunotherapy service in Japan. Under terms of the agreement, MaxCyte will provide the exclusive right to utilize its proprietary technology in the closed-system manufacturing of Medinet's immuno-cell therapy service in multiple cell processing centers across Japan based on optimized protocols developed under the MaxCyte-Medinet collaboration announced in August, 2006.
 Northern Therapeutics, Inc., a Canadian biotechnology company and MaxCyte, Inc are collaborating on the first-ever human trial of a novel, engineered cell-based therapy for the treatment of idiopathic (primary) pulmonary arterial hypertension (PAH), a rare but fatal cardiovascular disease that can strike in the prime of a person's life. The first patient in the trial received therapy at St. Michael's Hospital on November 7, 2006, and the procedure was well tolerated.
 Binex (KOSDAQ:053030) and MaxCyte, Inc. are collaborating to evaluate MaxCyte's GMP-compliant cell loading technology for use in closed-system manufacturing of Binex's cell-based cancer immunotherapies. Upon completion of the research studies, the agreement provides Binex an option to license MaxCyte's technology for clinical and commercial use in Korea.
|